RCS - Oxford Nanopore Tech - Presentation at 43rd Annual J.P. Morgan Conference

Oxford Nanopore TechnologiesAnnouncement

07/01/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250107:nRSG2898Sa&default-theme=true

RNS Number : 2898S  Oxford Nanopore Technologies plc  07 January 2025

 

Oxford Nanopore Technologies plc

Oxford Nanopore to Present at 43rd Annual J.P. Morgan Healthcare Conference

7 January 2025

Oxford Nanopore Technologies plc (LSE: ONT) ("Oxford Nanopore"), the company
delivering a new generation of nanopore-based molecular sensing technology,
will participate in the 43rd Annual J.P. Morgan Healthcare Conference at the
Westin St. Francis Hotel, San Francisco, California, USA.

 

Gordon Sanghera, Chief Executive Officer, will present on Monday, 13 January
2025 at 11:15 - 11:55am PST / 7:15 - 7:55pm GMT. The 40-minute session will
include a presentation and a moderated Q&A discussion.

 

A live webcast
(https://jpmorgan.metameetings.net/events/healthcare25/sessions/58139-oxford-nanopore-technologies/webcast?gpu_only=true&kiosk=true)
of the presentation and Q&A session can be accessed via the Investor
Relations section of Oxford Nanopore's website at:
https://nanoporetech.com/about-us/investors/reports
(https://nanoporetech.com/about-us/investors/reports) . A replay will be
available for at least 30 days following the event via the same link.

 

 

 ENDS 

 

For further information, please contact:

Oxford Nanopore Technologies plc

Investors:          ir@nanoporetech.com (mailto:ir@nanoporetech.com)

Media:              media@nanoporetech.com
(mailto:media@nanoporetech.com)

 

Teneo (communications adviser to the Company)

Tom Murray, Jo Blackshaw

+44 (0) 20 7353 4200

OxfordNanoporeTechnologies@teneo.com
(mailto:OxfordNanoporeTechnologies@teneo.com)

 

 

About Oxford Nanopore Technologies plc:

Oxford Nanopore Technologies' goal is to bring the widest benefits to society
through enabling the analysis of anything, by anyone, anywhere. The Group has
developed a new generation of nanopore-based sensing technology that is
currently used for real-time, high-performance, accessible, and scalable
analysis of DNA and RNA. The technology is used in more than 125 countries, to
understand the biology of humans, plants, animals, bacteria, viruses and
environments as well as to understand diseases such as cancer.  Oxford
Nanopore's technology also has the potential to provide broad, high impact,
rapid insights in a number of areas including healthcare, food and
agriculture.

For more information please visit: www.nanoporetech.com
(http://www.nanoporetech.com/)

 

 

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRABFMITMTIMBFA